Ocular Therapeutix Inc. (OCUL) Financial Statements (2025 and earlier)

Company Profile

Business Address 15 CROSBY DRIVE
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments195,807102,300164,164228,05754,43754,062
Cash and cash equivalent195,807102,300164,164228,05754,43754,062
Restricted cash and investments 150     
Receivables26,17921,32521,13512,2522,548201
Inventory, net of allowances, customer advances and progress billings2,3051,9741,2501,201954217
Inventory2,3051,9741,2501,201954217
Other undisclosed current assets7,7944,0284,7514,6502,2311,713
Total current assets:232,235129,627191,300246,16060,17056,193
Noncurrent Assets
Operating lease, right-of-use asset6,4728,0424,8675,8446,655
Property, plant and equipment11,7399,8566,9568,09510,15110,236
Restricted cash and investments1,6141,7641,7641,7641,7646,614
Total noncurrent assets:19,82519,66213,58715,70318,57016,850
TOTAL ASSETS:252,060149,289204,887261,86378,74073,043
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities33,05529,22024,71317,01610,9039,159
Accounts payable4,3895,1234,5922,7093,2682,965
Accrued liabilities28,66624,09720,12114,3077,6356,194
Deferred revenue255576   
Debt    8,2901,126 
Other undisclosed current liabilities1,5861,5991,6241,358  
Total current liabilities:34,89631,39526,33726,66412,0299,159
Noncurrent Liabilities
Long-term debt and lease obligation74,92554,00657,35948,79158,21724,788
Long-term debt, excluding current maturities74,92554,00651,43541,24349,31224,788
Liabilities, other than long-term debt51,10828,50933,192110,31312,1243,221
Deferred revenue and credits3,221
Deferred revenue14,13513,38713,00012,000 
Other liabilities10893    
Operating lease, liability6,8788,6785,9247,5488,905
Derivative instruments and hedges, liabilities29,9876,35120,19298,31312,124 
Total noncurrent liabilities:126,03382,51590,551159,10470,34128,009
Total liabilities:160,929113,910116,888185,76882,37037,168
Equity
Equity, attributable to parent91,13135,37987,99976,095(3,630)35,875
Common stock1288854
Additional paid in capital788,697652,213633,795615,338379,980333,114
Accumulated deficit(697,578)(616,842)(545,804)(539,251)(383,615)(297,243)
Total equity:91,13135,37987,99976,095(3,630)35,875
TOTAL LIABILITIES AND EQUITY:252,060149,289204,887261,86378,74073,043

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues58,44351,49443,52217,4034,2271,990
Cost of revenue(5,281)(4,540)(4,407)(2,083)(2,325)(465)
Cost of product and service sold(5,281)(4,540)(4,406)(2,083)(2,325) 
Gross profit:53,16246,95439,11515,3201,9021,525
Operating expenses(135,544)(125,608)(117,152)(78,167)(87,704)(60,643)
Operating loss:(82,382)(78,654)(78,037)(62,847)(85,802)(59,118)
Nonoperating income (expense)1,6467,61671,484(92,789)(570)(860)
Investment income, nonoperating3,983798331681,229879
Interest and debt expense14,190(7,022)(6,671)(6,768)(6,101)(1,739)
Loss from continuing operations:(66,546)(78,060)(13,224)(162,404)(92,473)(61,717)
Loss before gain (loss) on sale of properties:(13,224)(162,404)(92,473)(61,717)
Other undisclosed net income (loss)(14,190)7,0226,6716,768178,8451,739
Net income (loss):(80,736)(71,038)(6,553)(155,636)86,372(59,978)
Other undisclosed net loss attributable to parent     (172,744) 
Net loss available to common stockholders, basic:(80,736)(71,038)(6,553)(155,636)(86,372)(59,978)
Interest on convertible debt 4,1724,5964,409   
Dilutive securities, effect on basic earnings per share 4,502(13,841)(78,121)   
Other undisclosed net loss available to common stockholders, diluted (14,907)     
Net loss available to common stockholders, diluted:(86,969)(80,283)(80,265)(155,636)(86,372)(59,978)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(80,736)(71,038)(6,553)(155,636)86,372(59,978)
Comprehensive income (loss):(80,736)(71,038)(6,553)(155,636)86,372(59,978)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (172,744) 
Comprehensive loss, net of tax, attributable to parent:(80,736)(71,038)(6,553)(155,636)(86,372)(59,978)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: